The European Medicines Agency (EMA) on Friday rejected a French request to tighten prescription guidelines on types of birth-control pills linked with a relatively higher risk of blood clots.
A panel reviewed the evidence and concluded that the "benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks," the EU watchdog said, using the medical term for contraceptive pills.
"There is no reason for women who have been using CHCs without any problem to stop taking them on the basis of this review."
In January, France asked the EMA to modify prescription guidelines for so-called third- and fourth-generation of the pill, which were introduced in the 1990s and in the last decade respectively.
These contain synthetic versions of the female progestogen, which the makers say avoid some of the side-effects of older formulations.
A Danish study in 2011 found that women who used later generations of the pill ran twice the risk of developing blood clots, known as venous thromboembolism (VTE), compared to those who used older-generation drugs.
Compared with non-users of the Pill, the risk of a clot was three to six times higher. A VTE can be dangerous as clots formed in the veins can break up and be transported to the heart or lungs.
In absolute terms, though, the risk is low, experts have said.
In its review, the EMA's Pharmacovigilance Risk Assessment Committee found that the risk of VTEs with all contraceptives "is small," the agency said.
"There are small differences between the CHCs depending on the type of progestogen they contain," it added.
The EMA said it recommended updating the product information leaflet for birth control pills "to help women make informed decisions about their choice of contraception."
It also recalled advice to doctors to make regular assessments about the risk of blood clots to any patient who is taking contraceptive pills.
Risk factors include smoking, migraines, being overweight and increasing signs of ageing, the agency noted.
France had wanted the EMA to recommend that doctors no longer prescribe later-generation pills as a first option.
The health ministry also dropped the two later generations of the pill from the list of medications that are reimbursed under France's national health insurance programme.
Explore further: EU drug agency to review safety of new-generation Pill (Update)
© 2013 AFP
Medical Xpress on facebook
Related Stories
EU drug agency to review safety of new-generation Pill (Update)
Jan 28, 2013
The European Medicines Agency (EMA) on Monday said it would review safety data for third- and fourth-generation birth control pills, responding to French concern that these contraceptives may cause dangerous blood clots.
French health estimates delve into Pill risk
Mar 26, 2013
A French drug watchdog on Tuesday released estimates for blood clots linked to birth control pills in the wake of fears that so-called third- and fourth-generation oral contraceptives boost a small risk of dangerous thrombosis.
France at odds with European medicines agency over Pill (Update)
Jan 03, 2013
France insisted Friday on restricting the prescription of newer-generation birth control pills even as Europe's medicines watchdog declared there was no evidence to back a health warning.
Acne pill benefits outweigh blood clot risk: EU agency
May 17, 2013
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
France at odds with European medicines agency over Pill
Jan 11, 2013
France insisted Friday on restricting the prescription of newer-generation birth control pills even as Europe's medicines watchdog declared there was no evidence to merit a health warning.
Recommended for you
Teva Pharma plans to cut about 5,000 employees (Update)
Oct 10, 2013
Teva Pharmaceutical Industries Ltd. plans to cut about 5,000 employees mostly by the end of next year as part of a restructuring designed to slim the drugmaker's business and make it more efficient.
Adempas approved to treat pulmonary hypertension
Oct 09, 2013
(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.
Big data reaps big rewards in drug safety
Oct 09, 2013
Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report ...
Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
Oct 09, 2013
The German Institute for Quality and Efficiency in Health Care (IQWiG) analysed additional data on drugs from the group of gliptins. The drug manufacturers had subsequently submitted these data to the Federal Joint Committee ...
IQWiG: Reliable assessment of drugs is only possible on the basis of clinical study reports (CSRs)
Oct 09, 2013
In 2012 researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG) presented a study in the BMJ analysing information sources used in 16 health technology assessment (HTA) reports of drugs ("benefit ...
French families file suit over alleged blood-thinner deaths
Oct 09, 2013
The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.
User comments
© Medical Xpress 2011-2013, Phys.org network
The European Medicines Agency (EMA) on Friday rejected a French request to tighten prescription guidelines on types of birth-control pills linked with a relatively higher risk of blood clots.
A panel reviewed the evidence and concluded that the "benefits of all combined hormonal contraceptives (CHCs) continue to outweigh risks," the EU watchdog said, using the medical term for contraceptive pills.
"There is no reason for women who have been using CHCs without any problem to stop taking them on the basis of this review."
In January, France asked the EMA to modify prescription guidelines for so-called third- and fourth-generation of the pill, which were introduced in the 1990s and in the last decade respectively.
These contain synthetic versions of the female progestogen, which the makers say avoid some of the side-effects of older formulations.
A Danish study in 2011 found that women who used later generations of the pill ran twice the risk of developing blood clots, known as venous thromboembolism (VTE), compared to those who used older-generation drugs.
Compared with non-users of the Pill, the risk of a clot was three to six times higher. A VTE can be dangerous as clots formed in the veins can break up and be transported to the heart or lungs.
In absolute terms, though, the risk is low, experts have said.
In its review, the EMA's Pharmacovigilance Risk Assessment Committee found that the risk of VTEs with all contraceptives "is small," the agency said.
"There are small differences between the CHCs depending on the type of progestogen they contain," it added.
The EMA said it recommended updating the product information leaflet for birth control pills "to help women make informed decisions about their choice of contraception."
It also recalled advice to doctors to make regular assessments about the risk of blood clots to any patient who is taking contraceptive pills.
Risk factors include smoking, migraines, being overweight and increasing signs of ageing, the agency noted.
France had wanted the EMA to recommend that doctors no longer prescribe later-generation pills as a first option.
The health ministry also dropped the two later generations of the pill from the list of medications that are reimbursed under France's national health insurance programme.
Explore further: EU drug agency to review safety of new-generation Pill (Update)
© 2013 AFP
Medical Xpress on facebook
Related Stories
EU drug agency to review safety of new-generation Pill (Update)
Jan 28, 2013
The European Medicines Agency (EMA) on Monday said it would review safety data for third- and fourth-generation birth control pills, responding to French concern that these contraceptives may cause dangerous blood clots.
French health estimates delve into Pill risk
Mar 26, 2013
A French drug watchdog on Tuesday released estimates for blood clots linked to birth control pills in the wake of fears that so-called third- and fourth-generation oral contraceptives boost a small risk of dangerous thrombosis.
France at odds with European medicines agency over Pill (Update)
Jan 03, 2013
France insisted Friday on restricting the prescription of newer-generation birth control pills even as Europe's medicines watchdog declared there was no evidence to back a health warning.
Acne pill benefits outweigh blood clot risk: EU agency
May 17, 2013
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
France at odds with European medicines agency over Pill
Jan 11, 2013
France insisted Friday on restricting the prescription of newer-generation birth control pills even as Europe's medicines watchdog declared there was no evidence to merit a health warning.
Recommended for you
Teva Pharma plans to cut about 5,000 employees (Update)
Oct 10, 2013
Teva Pharmaceutical Industries Ltd. plans to cut about 5,000 employees mostly by the end of next year as part of a restructuring designed to slim the drugmaker's business and make it more efficient.
Adempas approved to treat pulmonary hypertension
Oct 09, 2013
(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.
Big data reaps big rewards in drug safety
Oct 09, 2013
Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report ...
Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
Oct 09, 2013
The German Institute for Quality and Efficiency in Health Care (IQWiG) analysed additional data on drugs from the group of gliptins. The drug manufacturers had subsequently submitted these data to the Federal Joint Committee ...
IQWiG: Reliable assessment of drugs is only possible on the basis of clinical study reports (CSRs)
Oct 09, 2013
In 2012 researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG) presented a study in the BMJ analysing information sources used in 16 health technology assessment (HTA) reports of drugs ("benefit ...
French families file suit over alleged blood-thinner deaths
Oct 09, 2013
The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment